UAE

Awiqli® changes that by offering a single weekly dose, giving patients greater flexibility to fit treatment into their individual lifestyles and preferences.

The new facility adds to Tajmeel’s growing portfolio of over 30 specialized treatments spanning beauty, regenerative medicine, and surgical transformation.

The partnership directly supports Dubai’s D33 Economic Agenda and aims to establish the emirate as a global leader in HealthTech innovation.

The Intracept™ Procedure targets the basivertebral nerve, which carries pain signals from damaged vertebral endplates.

The trial, developed by US-based biopharmaceutical company Opus Genetics, marks a significant step forward in the Emirate’s growing ambition to become a global hub for life sciences and biomedical innovation.

The new facility operates as a fully smart, digital-first outpatient center that connects appointments, consultations, diagnostics, pharmacy services, and follow-up care through integrated digital systems.

The healthcare centre serves more than 70,000 patients annually from across Jerash Governorate and neighboring areas, making it a vital healthcare resource for the region.

Al Jalila Children’s Hospital’s Pediatric Cardiology service currently performs approximately 200 pediatric cardiac surgeries annually.

The partnership will bring select consultant vascular and endovascular surgeons from Sir Ganga Ram Hospital’s IVES to C37’s Dubai facility.

Abdallah previously served as Chief Investment Officer and has maintained close involvement with Cambridge Health Group for several years.